Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuroendocrine Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    292 result(s) found for: Neuroendocrine Cancer. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-005238-31 Sponsor Protocol Number: TENEC Start Date*: 2017-03-13
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Progressing after First-Line Platinum- based Therapy
    Medical condition: Neuroendocrine Carcinomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000240-16 Sponsor Protocol Number: 20110106 Start Date*: 2011-06-12
    Sponsor Name:Skånes Onkologiska Klinik, Skåne University Hospital, Lund
    Full Title: A MULTICENTER PHASE II STUDY EVALUATING EFFICACY AND SAFETY OF 177Lu-DOTA-TATE BASED ON KIDNEY-DOSIMETRY IN PATIENTS WITH DISSEMINATED NEUROENDOCRINE TUMORS
    Medical condition: Metastatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003268-11 Sponsor Protocol Number: IEO676 Start Date*: 2019-02-20
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC in patients with somatostatin receptor positive tumors (neuroendocrine tumors)
    Medical condition: Neuroendocrine tumors in progression of disease and not suitable to additional treatments, positive to SSTR
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001099-13 Sponsor Protocol Number: CRAD001K24133E1 Start Date*: 2012-05-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors
    Medical condition: advanced neuroendocrine tumors of gastrointestinal or lung origin
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003768-30 Sponsor Protocol Number: IEO906 Start Date*: 2019-11-12
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in pancreatic neuroendocrine tumors
    Medical condition: Pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002741-21 Sponsor Protocol Number: AAA-Ga-TOC-EU-01 Start Date*: 2014-10-23
    Sponsor Name:Advanced Accelerator Applications SA
    Full Title: Safety and tolerability of 68Ga-DOTATOC for injection in patients with proven gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
    Medical condition: Patients with proven gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001613-83 Sponsor Protocol Number: IMMUNeOCT Start Date*: 2017-07-11
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: Octreotide LAR in the induction of immunologic response in patient with neuroendocrine tumors: an interventional pharmacological study
    Medical condition: patient with neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006234-16 Sponsor Protocol Number: INT003 Start Date*: 2012-03-27
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Evaluation of the efficacy of the tandem treatment [90Y-DOTA, TYR(3)]OCTREOTATE and [177Lu-DOTA, TYR(3)]OCTREOTATE in patients with neuroendocrine tumour expressing somatostatin receptors and refra...
    Medical condition: Patients bearing neuroendocrine tumour expressing somatostatin receptors refractory to conventional therapies
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006097-76 Sponsor Protocol Number: LOTUS Start Date*: 2013-01-11
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: RANDOMIZED PHASE 3 TRIAL EVALUATING THE EFFICACY OF LOCOREGIONAL TREATMENT WITH TRANSARTERIAL EMBOLIZATION (TAE) FOR LIVER METASTASIS, IN COMBINATION WITH OCTREOTIDE LAR, IN PATIENTS WITH NEUROENDO...
    Medical condition: PATIENTS WITH NEUROENDOCRINE TUMOR AND INOPERABLE LIVER METASTASIS
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005202-10 Sponsor Protocol Number: IEO388 Start Date*: 2016-07-06
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: An open label, single-center, not controlled, exploratory study to develop and evaluate the application of a new technique of radioguided surgery in gastro-entero-pancreatic neuroendocrine tumors (...
    Medical condition: Gastro-entero-pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005393-10 Sponsor Protocol Number: IEO1411 Start Date*: 2021-09-21
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: An Italian multicenter phase II trial of Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms (NENs): MeTe study
    Medical condition: Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003640-88 Sponsor Protocol Number: D-FR-01072-004 Start Date*: 2022-01-26
    Sponsor Name:Ariceum Therapeutics GmbH
    Full Title: A Multicentre Surveillance Study to Evaluate the Long-term Safety in Participants who Have Been Previously Treated with 177Lu-IPN01072 in an Ipsen-sponsored Clinical Study
    Medical condition: Neuroendocrine tumors (NETs)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001467-39 Sponsor Protocol Number: GETNE1509 Start Date*: 2015-07-24
    Sponsor Name:GETNE (Grupo Español de Tumores Neuroendocrinos)
    Full Title: A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin.
    Medical condition: Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohor...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002872-17 Sponsor Protocol Number: CSOM230DIC03 Start Date*: 2013-06-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Multicenter 3-arm trial to evaluate the efficacy and safety of Pasireotide LAR or Everolimus alone or in combination in patients with well differentiated neuroendocrine carcinoma of the lung and th...
    Medical condition: Neouroendocrine carcinoma of the lung and thymus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025064 Lung carcinoma LLT
    20.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Prematurely Ended) SE (Prematurely Ended) ES (Completed) FR (Prematurely Ended) NL (Prematurely Ended) DK (Completed) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002887-26 Sponsor Protocol Number: CRAD001T2302 Start Date*: 2012-04-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, multicenter, Phase III study of everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced NET of ...
    Medical condition: Advanced neuroendocrine tumor (NET) of GI or lung origin
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) CZ (Completed) HU (Completed) ES (Completed) GB (Completed) IT (Completed) NO (Completed) NL (Completed) GR (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002858-20 Sponsor Protocol Number: ESR-15-11561-61/DUNE Start Date*: 2017-03-02
    Sponsor Name:GETNE (Grupo Español de Tumores Neuroendocrinos)
    Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin (the DUNE trial).
    Medical condition: Advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-001306-30 Sponsor Protocol Number: PROICM2021-04REL Start Date*: 2021-09-13
    Sponsor Name:Institut Régional du Cancer de Montpellier
    Full Title: A prospective randomized phase II study to assess the schemas of retreatment with Lutathera® ([177Lu]Lu-DOTA-TATE) in patients with new progression of intestinal well-differentiated neuroendocrine ...
    Medical condition: Patients with new progression of intestinal well-differentiated neuroendocrine tumor.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006160-48 Sponsor Protocol Number: HE67/12 Start Date*: 2012-05-07
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: Phase II multicenter single-arm study evaluating the safety and efficacy of everolimus as a first-line treatment in newly-diagnosed patients with advanced GI neuroendocrine tumors.
    Medical condition: Well or moderately differentiated advanced (metastatic or unresectable) GI or pancreatic neuroendocrine tumors.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022273-34 Sponsor Protocol Number: CRAD001KDE37 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A multi-centric, open-label, phase II study investigating the combination of Afinitor with paclitaxel and carboplatin in first line treatment of patients with advanced (stage IV) large cell lung c...
    Medical condition: large-cell neuroendocrine carcinoma of the lung
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001016-30 Sponsor Protocol Number: NODAGA-RGD-2 Start Date*: 2018-12-11
    Sponsor Name:Department of Nuclear Medicine, Medical University Innsbruck
    Full Title: PROSPECTIVE STUDY OF 68GA-NODAGA-RGD-PET FOR THE NON-INVASIVE DETERMINAITON OF THE INTEGRIN αvβ3 EXPRESSION IN PATIENTS WITH UNTREATED OR RECURRENT BREAST CANCER, COLORECTAL CANCER, NON-SMALL CELL ...
    Medical condition: Patient with untreated or reccurent breast cancer, non-small cell lung cancer, colorectal cancer and neuroendocrine tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:00:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA